| Trial ID: | L6485 |
| Source ID: | NCT05501483
|
| Associated Drug: |
Pioglitazone 45 Mg
|
| Title: |
Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
|
| Acronym: |
DiaSpax
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Pioglitazone 45 mg|DRUG: Empagliflozin 25 MG|DRUG: Semaglutide 7 MG
|
| Outcome Measures: |
Primary: Changes in fat cell lipolysis after 6 months of treatment, Change in isoprenaline-induced (over basal) lipolysis in isolated fat cells, Baseline and after six months intervention | Secondary: Changes in fat cell heterogeneity after 6 months of treatment, Changes in the adiponectin/leptin mRNA expression ratio in adipose tissue measured by quantitative PCR, Baseline and after six months intervention | Other: Changes in tissue cellularity after 6 months of treatment (explorative outcome), Changes in adipose tissue cellularity measured by single-cell transcriptomic analyses of fat tissue biopsies, Baseline and after six months intervention
|
| Sponsor/Collaborators: |
Sponsor: Karolinska Institutet | Collaborators: Karolinska University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2023-02-08
|
| Completion Date: |
2032-12-31
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-26
|
| Locations: |
Karolinska University Hospital, Stockholm, 14186, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT05501483
|
